PNU-99,194
 | |
| Clinical data | |
|---|---|
| Routes of administration | Oral |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
JSmol) | |
| |
PNU-99,194(A) (or U-99,194(A)) is a
D2 subtype.[1][2][3] Though it has substantially greater preference for D3 over D2, the latter receptor does still play some role in its effects, as evidenced by the fact that PNU-99,194 weakly stimulates both prolactin secretion and striatal dopamine synthesis, actions it does not share with the more selective (100-fold) D3 receptor antagonists S-14,297 and GR-103,691.[4]
In
Other effects of PNU-99,194 at low doses in rodents include increased
behavioral sensitization,[18][19] and reversal of morphine-induced CPP.[6] At high doses it inhibits the self-administration of cocaine in both rats and monkeys.[1][20]
See also
References
- ^ S2CID 39482275.
- ^ S2CID 32918280.
- ^ S2CID 10327706.
- ^ PMID 9765337.
- ^ S2CID 30848393.
- ^ S2CID 2721240.
- ^ S2CID 20542615.
- ^ S2CID 1592299.
- S2CID 41821358.
- S2CID 20953625. Archived from the originalon 2000-07-12. Retrieved 2010-04-30.
- S2CID 46728735.
- ^ S2CID 45464906.
- S2CID 1004412.
- PMID 11334239.
- S2CID 24086632.
- S2CID 24698131.
- S2CID 10007327.
- S2CID 1840764.
- S2CID 40067321.
- S2CID 12383682.